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Abstract
Aim: To conduct a comprehensive review of studies of glycaemic deterioration in 
type 2 diabetes and identify the major factors influencing progression.
Methods: We conducted a systematic literature search with terms linked to type 2 di-
abetes	progression.	All	the	included	studies	were	summarized	based	upon	the	factors	
associated with diabetes progression and how the diabetes progression was defined.
Results: Our	search	yielded	2785	articles;	based	on	title,	abstract	and	full-text	re-
view,	we	included	61	studies	in	the	review.	We	identified	seven	criteria	for	diabetes	
progression:	‘Initiation	of	insulin’,	‘Initiation	of	oral	antidiabetic	drug’,	‘treatment	in-
tensification’,	‘antidiabetic	therapy	failure’,	‘glycaemic	deterioration’,	‘decline	in	beta-
cell	function’	and	‘change	in	insulin	dose’.	The	determinants	of	diabetes	progression	
were	grouped	into	phenotypic,	ethnicity	and	genotypic	factors.	Younger	age,	poorer	
glycaemia	and	higher	body	mass	index	at	diabetes	diagnosis	were	the	main	pheno-
typic factors associated with rapid progression. The effect of genotypic factors on 
progression was assessed using polygenic risk scores (PRS); a PRS constructed from 
the genetic variants linked to insulin resistance was associated with rapid glycaemic 
deterioration. The evidence of impact of ethnicity on progression was inconclusive 
due to the small number of multi-ethnic studies.
Conclusion: We have identified the major determinants of diabetes progression—
younger	age,	higher	BMI,	higher	HbA1c	and	genetic	insulin	resistance.	The	impact	of	
ethnicity is uncertain; there is a clear need for more large-scale studies of diabetes 
progression in different ethnic groups.
K E Y W O R D S
diabetes	progression,	glycaemic	deterioration,	insulin	initiation,	type	2	diabetes
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1  | INTRODUC TION
Type	2	diabetes	 is	a	heterogeneous,	chronic	progressive	condition	
characterized by impaired beta-cell function and insulin resistance.1 
The increasing prevalence and rapid progression of diabetes account 
for the higher cost of the illness and disability-adjusted life years 
(DALY).2-4	In	order	to	prevent	or	delay	the	progression	of	diabetes,	
or even to target intervention more aggressively to those most likely 
to	 rapidly	progress,	we	need	to	understand	the	 factors	associated	
with the incidence and progression of diabetes.
To	date,	most	 research	has	 focused	on	 risk	 factors	 for	 the	de-
velopment of diabetes rather than the progression of diabetes after 
diagnosis.	 Lifestyle,	 obesity	 and	 reduced	 physical	 activity	 are	 im-
portant factors associated with diabetes risk.5	 In	addition	to	these	
risk	 factors,	 there	 are	many	biomarkers	 associated	with	 increased	
incidence of diabetes. These are classified as glycaemic factors 
(HbA1c,	 fructosamine,	 glycated	 albumin,	 1-5-anhydroglucitol),	 ad-
ipose-derived	 factors	 (adiponectin,	 leptin),	 hepatic	 derived	 factors	
(alanine	 aminotransferase,	 ferritin,	 insulin-like	 growth	 factor	 1),	
endothelial-derived	 factors	 (cell	 adhesion	 molecules,	 tissue	 plas-
minogen	 activators)	 and	 inflammatory	 factors	 (c-reactive	 protein,	
interleukin-6	 (IL-6),	 interleukin-13	 (IL-13),	 interleukin-17	 (IL-17)).6-10 
Many	 studies	 assessed	 the	 role	of	 ethnicity	 in	diabetes	 incidence,	
and	the	Diabetes	Study	of	North	California	showed	higher	incidence	
rates	 in	 Asians	 compared	 with	 a	White	 American	 population.11-13 
Genotypic factors also play an important role in the development of 
diabetes. There are more than 400 single nucleotide polymorphisms 
(SNPs) associated with the incidence of diabetes.14 The effect of 
these SNPs is increasingly evaluated by constructing polygenic risk 
scores	(PRS),	whereby	the	individual	risk	alleles	are	summed	to	pro-
vide a genetic risk for each individual in a population. Studies of type 
2 diabetes PRS showed a significant association with risk of type 2 
diabetes	 after	 adjustment	 for	 other	 phenotypic	 factors,15-17 and a 
study conducted among Europeans demonstrated a 9.4-fold risk for 
individuals in the upper vs lower 2.5% of the PRS.14
While it is clearly important to understand diabetes risk factors 
to	prevent	the	onset	of	diabetes,	it	is	also	important	that	we	identify	
factors	which	drive	the	progression	after	the	onset	of	diabetes,	given	
the current huge prevalence of diabetes globally. There have been 
far fewer studies in this critical area. Criteria for diabetes progres-
sion after the onset of disease are mainly related to antidiabetic drug 
requirement	 (oral	hypoglycaemic	agents	 (OHA)s	or	 insulin	require-
ment),	drug	failure,	drug	addition,	increasing	drug	dosage,	glycaemic	
level	measured	as	HbA1c,	and	decline	 in	beta-cell	 function.	These	
wide-ranging definitions reflect a lack of consensus on how diabe-
tes	progression	is	defined	and	some,	but	not	all	of	these	measures,	
will be affected by factors related to the patient or prescriber rather 
than	the	true	underlying	progression.	That	said,	if	we	can	recognize	
the	key	 factors	 that	determine	diabetes	progression,	 this	will	help	
to identify the fast progressors enabling early intensified treatment 
and	provide	biological	insights	into	the	process	driving	progression,	
which may enable the development of targeted intervention to slow 
progression rates of diabetes. The objective of this review was to 
identify and summarize the factors determining type 2 diabetes pro-
gression,	reflecting	glycaemic	deterioration,	to	evaluate	the	impact	
of ethnicity on progression and to identify knowledge gaps where 
further research is required.
2  | MATERIAL S AND METHODS
A	comprehensive	 literature	search	was	conducted	 in	the	MEDLINE 
(PubMed) database to identify peer-reviewed published studies 
which	explored	determinants	of	diabetes	progression.	In	this	review,	
diabetes progression is defined as the progression of diabetes from 
diagnosis to clinical requirement of insulin or events indicating gly-
caemic deterioration. The major search terms used were “diabetes 
mellitus,	 type	 2",	 “diabetes	 progression”,	 “glycaemic	 deterioration”	
and	 “disease	 progression/epidemiology."	 These	 terms	were	 identi-
fied from the manuscripts related to type 2 diabetes progression or 
from the MeSH (Medical Subheading) database of MEDLINE.	A	de-
tailed	description	of	the	search	terms	used	is	provided	in	Appendix	
S1.	We	included	all	types	of	study	designs,	without	any	language	re-
striction from the database inception to search date (01/06/2019),	in	
order to capture all relevant studies. Studies across all ethnic groups 
are	included.	In	addition	to	searching	MEDLINE,	we	undertook	hand	
searches with cross-referencing to accommodate all the available 
studies.	 We	 excluded	 records	 which	 were	 (a)	 narrative	 reviews,	
guidelines	or	commentaries,	(b)	studies	of	type	1	diabetes,	(c)	studies	
assessing risk factors for diabetes and progression to diabetes from 
pre-diabetes or from a healthy state and (d) studies of progression 
during or following gestational diabetes mellitus.
2.1 | Data extraction and analysis
Literature	reduction	was	conducted	by	reviewing	the	title,	abstract	
and	full	paper-based	reviews	(Figure	1).	From	all	the	included	stud-
ies,	appropriate	data	was	extracted	 into	Excel	spreadsheets	which	
included	information	on	author,	publication	year,	study	design,	sam-
ple	size,	objective	of	the	study,	follow-up	period,	characteristics	of	
study	 population,	 indicator	 of	 diabetes	 progression,	 country	 and	
ethnicity	of	 the	 study	participants,	 factors	affecting	diabetes	pro-
gression and interpretation of study results. The review results have 
been summarized according to the identified determinants of diabe-
tes	progression,	design	of	the	study	and	how	the	diabetes	progres-
sion was defined (Table S1).
3  | RESULTS
The flow diagram of the literature reduction process is provided in 
Figure	 1.	 Our	 initial	 search	 without	 any	 filters	 provided	 2768	 re-
cords.	After	removing	duplicates,	2757	records	remained.	The	final	
article pool was created by adding the 28 hand-searched studies re-
sulting	 in	2785	records.	We	reviewed	the	2785	titles	and	selected	
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383	abstracts	based	on	its	relevance	to	diabetes	progression.	Based	
on	the	abstract	review,	we	retained	194	relevant	articles.	After	the	
full-text	review,	61	studies	were	included	in	the	review.
From	 the	 61	 included	 articles,	 56	 studies	 assessed	 the	 phe-
notypic	 factors	 affecting	 diabetes	 progression,18-73 while only 
four studies investigated genotypic determinants of diabetes 
progression74-77 and one study assessed both phenotypic and 
genotypic factors.78	 Before	 2000,	 there	 were	 only	 four	 studies	
published and between 2000 and 2010; there were 20 studies 
published,	 with	 the	 remaining	 37	 studies	 published	 after	 2010.	
The	 61	 studies	were	 comprised	 of	 35	 retrospective	 cohort	 stud-
ies,19,20,23,24,26-31,34,36-38,41,45,49-51,53,57,58,60-65,67-70,72,76 19 prospec-
tive	 cohort	 studies,21,22,32,33,35,39,40,42-44,46,48,52,54,56,59,66,71,73 three 
cross-sectional	 studies,18,25,47 three case-control studies74,75,77 
studies and one randomized controlled trial (RCT).79 The sample 
size	ranged	from	50	to	366	955	individuals,	and	most	of	the	stud-
ies	were	 from	developed	countries	with	European,	American	and	
Australian	populations.	Further	details	of	the	studies	are	provided	
in Table S1.
3.1 | Definitions of “diabetes progression”
There are multiple ways in which investigators have defined diabetes 
progression. We have identified seven criteria for progression from 
these	 studies:	 (a)	 “initiation	of	 insulin”:	 defined	 as	 the	 initiation	of	
first insulin prescription or the start of sustained use of insulin (more 
than	6	months);	 (b)	“initiation	of	oral	antidiabetic	drug”:	defined	as	
the initiation of first oral hypoglycaemic agent after the diagnosis 
of	 diabetes;	 (c)	 “treatment	 intensification”:	 defined	 as	 the	 process	
to	attain	glycaemic	control,	characterized	by	an	increase	in	the	dose	
of	 OHAs,	 adding	 more	 OHAs	 or	 commencing	 insulin	 therapy;	 (d)	
“antidiabetic	therapy	failure”:	 is	described	as	the	decline	of	the	ef-
fectiveness	of	OHAs	to	maintain	appropriate	glycaemic	levels	which	
result	in	shift	to	OHA	combination	therapy	or	insulin	administration;	
(e)	“glycaemic	deterioration”:	defined	as	an	increase	in	HbA1c	levels	
after	the	onset	of	diabetes	(HbA1c	>	8%	or	1%	rise	from	diagnosis)	
or rise of coefficient of failure (the coefficient of failure is the slope 
of	the	least	squares	regression	line	of	HbA1c	against	time)79; (f) “de-
cline	in	beta-cell	function”:	pancreatic	beta-cell	function	is	assessed	
F I G U R E  1  Flow	diagram	of	Literature	reduction	process
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by many methods such as homoeostasis model assessment–beta 
(HOMA	-B)	or	 fasting	C	peptide	or	proinsulin/insulin	 ratio;	and	 (g)	
“change	in	insulin	dose”:	an	increased	requirement	of	insulin	is	con-
sidered to reflect diabetes progression after the initiation of insulin.
The definition of diabetes progression was broken down in the 
61	studies	as	follows:	34	studies	used	“initiation	of	insulin”,	ten	used	
“treatment	intensification”,	seven	used	“initiation	of	oral	antidiabetic	
drug”,	five	used	“decline	in	beta-cell	function”,	three	used	“glycaemic	
deterioration”,	one	used	“therapy	failure”	and	one	used	“change	 in	
insulin	dose.”
3.2 | Phenotypic determinants of diabetes 
progression
Among	all	studies,	57	studies	primarily	assessed	the	role	of	pheno-
typic	factors	on	the	rate	of	diabetes	progression	of	which	56	studies	
assessed the role of phenotypic factors only and one study assessed 
both phenotypic and genotypic factors in regulating the diabetes 
progression.	Despite	there	being	more	than	35	biomarkers	for	the	
prediction	of	diabetes	incidence,	only	a	few	studies	have	attempted	
to identify biomarkers for diabetes progression.10 The major phe-
notypic factors associated with diabetes progression across these 
studies	were	glycaemia	measured	as	HbA1c	or	fasting	glucose,	age	
of	diabetes	onset,	BMI,	gender,	diabetes	duration,	high-density	lipo-
protein-cholesterol	(HDL-C)	and	triglycerides	(TG).
3.2.1 | Glycaemia
Twenty-six	 studies	 (20	 retrospective	 cohort	 stud-
ies,19,24,26,27,29,34,37,38,41,49,51,53,60-65,70,78 five prospective cohort stud-
ies46,48,52,54,71 and one RCT55)	reported	HbA1c	or	fasting	blood	glucose	
at diagnosis as one of the main determinants of diabetes progression.
The	Look	AHEAD	(Action	for	Health	in	Diabetes)	trial	was	con-
ducted to assess the effect of weight loss on the prevention of 
cardiovascular disease in obese/overweight type 2 diabetes cases. 
Study participants were randomized into intensive lifestyle interven-
tion	or	diabetes	support	education,	and	the	effect	on	cardiovascular	
disease	was	evaluated.	A	secondary	analysis	of	time	to	insulin	initi-
ation	demonstrated	an	adjusted	hazard	ratio	(aHR)	of	1.48	(95%	CI	
1.36-1.45)	per	1%	increase	in	baseline	HbA1c.55
From	five	prospective	studies,	three	used	insulin	initiation,46,48,52 
one used beta-cell dysfunction54 and one used secondary diet fail-
ure71 as the progression marker and all of them showed a significant 
association between more rapid insulin initiation and higher base-
line glycaemia. Three studies with insulin initiation as a marker of 
diabetes	progression	reported	aHRs	ranged	from	1.22	to	2.23	per	
1%	increase	in	baseline	HbA1c.46,48,52 The fourth prospective study 
assessed	predictors	of	beta-cell	stress,	using	proinsulin/insulin	(PI/I)	
ratio as a surrogate measure. The risk of beta-cell stress increased 
by	3.8	times	with	1%	increase	in	baseline	HbA1c.54 The fifth study 
was	 the	Belfast	Diet	 study	which	assessed	 failure	of	diet	 therapy.	
They	reported	that	a	lower	baseline	fasting	blood	glucose	(FBS)	was	
significantly associated with a slower rate of diabetes progression.71
Among	 the	20	 retrospective	cohort	 studies,	 eight	 assessed	 in-
sulin	 initiation,	 eight	 reported	 treatment	 intensification	 and	 four	
focused on drug initiation. Eight insulin initiation-based studies es-
timated the hazard of insulin initiation per 1% increase in baseline 
HbA1c	 (%)	and	aHR	varied	from	1.09	to	1.33.19,24,26,41,63,65,70,78	All	
eight studies which assessed diabetes progression on the basis of 
treatment	intensification	reported	baseline	HbA1c	was	significantly	
associated with rapid treatment intensification.29,37,38,51,53,60-62	 A	
study	conducted	in	France	assessed	the	hazard	of	different	catego-
ries	of	baseline	HbA1c	with	HbA1c	≤	7%	as	a	reference	in	relation	
to treatment intensification. Hazard ratios for different categories 
of	baseline	HbA1c	were	7.01%-8.5%	(aHR:	1.51),	8.51%-9.5%	(aHR:	
2.16)	and	≥9.51%	(aHR:1.38).	In	contrast	to	the	other	study	findings,	
F I G U R E  2   Major factors at diagnosis influencing diabetes progression (factors reported by at least two studies)
     |  5 of 11THAKARAKKATTIL NARAYANAN NAIR eT AL.
there	was	an	unexplained	reduction	in	aHR	at	the	higher	HbA1c	(%)	
category compared with other categories.29	Of	the	four	studies	as-
sessing diabetes progression with antidiabetic drug initiation as a 
sign	of	progression,	two	studies	showed	higher	glycaemia	level	(fast-
ing	blood	sugar	or	HbA1c)	was	associated	with	antidiabetic	drug	pre-
scription.34,49	The	other	two	studies	reported	higher	HbA1c	 levels	
were associated with shorter time to antidiabetic drug initiation with 
an	aHR	of	2.44	(95%	CI	1.61-3.70)	for	HbA1c	greater	than	7.5%.27,64
Overall,	HbA1c	at	diagnosis	is	reported	as	a	significant	determi-
nant	of	diabetes	progression	by	20	retrospective,	 five	prospective	
and	one	RCT	studies	as	summarized	in	Figure	2.	HbA1c	is	a	key	fac-
tor determining diabetes progression: irrespective of the difference 
in	 the	 study	 population	 and	 follow-up,	 nearly	 all	 studies	 reported	
the	 importance	 of	 higher	 HbA1c	 with	 increased	 risk	 of	 diabetes	
progression.
3.2.2 | Age of onset of diabetes and 
duration of diabetes
A	total	of	27	studies	established	the	association	of	younger	age	of	
diabetes	 onset	 with	 increased	 diabetes	 progression.	 Of	 these,	 22	
were	 retrospective,19,23,26,27,29,30,34,37,45,49-51,60-65,70,72,78 three were 
prospective,43,71,73	one	was	a	RCT,55 and one was a cross-sectional 
study.18
Analysis	of	the	Look	AHEAD	trial	data	showed	that	younger	age	
of diabetes diagnosis was associated with faster rate of insulin ini-
tiation,	with	an	aHR	0.88	(95%	CI	0.79-0.98)	per	10	year	of	age	of	
diagnosis.55	In	the	prospective	studies,	two	studies	used	time	to	in-
sulin,43,73	and	one	used	diet	failure	as	the	progression	phenotype,71 
with all three studies concluding that younger age of diagnosis was 
associated with faster progression.43,71,73
Of	 the	 22	 retrospective	 studies,	 10	 examined	 the	 relationship	
between time to insulin and age of diabetes19,23,24,26,30,63,65,70,72,78 
while	seven	assessed	time	to	treatment	intensification,29,37,45,51,60-62 
four assessed the initiation of antidiabetic drug27,34,49,64 and one 
evaluated glycaemic deterioration.50 Most of the retrospective stud-
ies which considered initiation of insulin as a progression marker re-
ported that a younger age at diagnosis is associated with a higher 
risk of diabetes progression. While two studies reported age as a 
risk	 factor	 for	 insulin	 initiation,	 of	 these	 one	 study	 compared	 the	
insulin initiation with other antidiabetic injectables and the final 
study assessed early vs late insulin initiation.23,26	A	 significant	 as-
sociation between diabetes progression and age of diabetes was 
reported	by	all	other	longitudinal	studies,	even	though	the	markers	
of	progression	were	different.	In	contrast	to	the	above	findings,	one	
cross-sectional study which used self-reported information on in-
sulin initiation described that higher age group was associated with 
early insulin initiation.18
Eight	studies	examined	the	relationship	between	time	to	insulin	
and	diabetes	duration,	of	these	six	were	retrospective20,23,41,61,65,69 
and two were prospective cohort studies.46,73	Diabetes	duration	is	
defined as the time between diabetes diagnosis and entry into the 
study. Most of the studies used insulin initiation as a marker of dia-
betes progression. Most of these studies reported that participants 
with longer diabetes duration were more likely to start insulin early 
compared to those with short duration.
3.2.3 | Adiposity-related factors
One	of	the	main	adiposity-related	features	associated	with	diabetes	
progression	was	BMI.	 In	 some	 studies,	weight	 or	waist	 circumfer-
ence was used as an alternative measure of adiposity. There were 20 
studies that measured the effect of adiposity on diabetes progres-
sion:	 13	 retrospective,19,20,34,37,41,49,50,53,60,63,65,67,78 five prospec-
tive,32,46,48,56,71 one cross-sectional18 and one RCT.55
The	Look	AHEAD	trial	reported	a	5%	increase	in	hazard	of	insu-
lin initiation with every 5 kg/m2	 increase	in	BMI.55 Two of the five 
prospective studies used weight71 and waist circumference32 as a 
measure of adiposity. Two of the prospective cohort studies used in-
sulin	initiation	as	a	marker	of	progression,	while	secondary	diet	fail-
ure,	glycaemic	deterioration	and	beta-cell	dysfunction	were	used	in	
the other studies. The follow-up period of these five studies ranged 
from	2	to	10	years,	and	most	of	them	were	conducted	in	developed	
countries. The time to insulin studies showed that with each 1 kg/
m2	increase	in	baseline	BMI	the	hazard	of	insulin	initiation	increased	
by between 1% and 8%.46,48	Similarly,	a	cohort	study	with	131	indi-
viduals demonstrated a one inch (2.25 cm) increase in waist circum-
ference	was	associated	with	increased	risk	of	progression	(aHR	3.13	
(95%	CI	1.11-8.91)).32	To	summarise,	four	studies	showed	higher	adi-
posity was associated with rapid progression32,46,48,71 and one study 
reported	lower	BMI	was	related	to	beta-cell	dysfunction.56
Among	the	13	retrospective	studies,	seven	assessed	insulin	initi-
ation,19,20,41,63,65,67,78	three	assessed	treatment	intensification,37,53,60 
two assessed initiating antidiabetic drugs34,49 and one assessed gly-
caemic deterioration.50 Three time to insulin and treatment intensi-
fication-based studies reported faster progression to insulin in those 
with	higher	BMI.20,37,53,60,63,65	Contrary	to	this,	a	lower	BMI	was	as-
sociated with faster progression to insulin in two retrospective stud-
ies.19,41	 These	 findings	 are	 consistent	 with	 the	 IMI-DIRECT	 study	
which	 demonstrated	 a	 “U-shaped”	 relationship	 between	 diabetes	
progression	 (time	 to	 insulin)	 and	 BMI.	 This	 indicates	 that	 diabetic	
individuals	with	lower	and	higher	levels	of	BMI	progress	faster	com-
pared	with	the	normal	BMI	group.78	Although	the	study	designs	and	
progression	indicators	varied	across	studies,	they	all	suggested	base-
line obesity as a risk factor for rapid diabetes progression.18,34,49,50,67
3.2.4 | Gender
In	most	of	 the	studies,	 female	gender	was	associated	with	greater	
progression to insulin initiation. There were two prospective co-
hort	studies	and	nine	retrospective	studies	in	this	group,	and	most	
of the studies reported time to insulin initiation. The two prospec-
tive	studies	differed,	with	one	study	reporting	female	gender	with	
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increased	hazard	of	insulin	initiation	compared	with	men	(aHR	2.13,	
95%	CI	1.08-4.21),48 while the other study reported female gender 
as	protective	for	insulin	initiation	(aHR	0.95,	95%	CI	0.90-0.99)	with	
marginal significance.46 Two retrospective studies also described fe-
male	gender	as	a	protective	factor	for	progression,19,37 but the seven 
remaining studies had different findings and reported an aHR of fe-
male	gender	between	1.03	and	1.20	in	relation	to	diabetes	progres-
sion compared with men.20,61,63,64,70,72,78
3.2.5 | Lipid-related factors
HDL-c,	 LDL-c	 and	 triglycerides	 have	 been	 reported	 to	 be	 associ-
ated	with	diabetes	progression.	Five	studies	assessed	the	effect	of	
baseline	HDL-c	on	diabetes	progression.	Among	these	five	studies,	
one	study	was	prospective	in	design,	but	all	studies	provided	identi-
cal	results:	 increased	HDL-c	was	a	protective	factor	and	it	delayed	
the	 glycaemic	 deterioration,	 oral	 antidiabetic	 drug	 initiation	 or	 in-
sulin initiation.40,41,49,50,78	 In	 addition,	 the	 ratio	 between	 HDL-c/
apolipoprotein	 A-I	 and	 M-HDL-subclasses	 also	 delayed	 diabetes	
progression.40,59
A	 significant	 association	 was	 detected	 between	 higher	 LDL-c	
and increased diabetes progression in one retrospective study.41 
The association between baseline triglyceride levels and diabetes 
progression was investigated by four retrospective studies. Three 
of them showed an increased risk of progression with increased tri-
glycerides,34,41,78 while in one study among a poorly controlled dia-
betes	group,	lower	triglyceride	within	a	high	HbA1c	group	had	rapid	
insulin	 requirement	 relative	 to	 the	 high	 triglyceride-lower	 HbA1c	
group.23	These	analyses	were	adjusted	 for	BMI,	but	not	waist	 cir-
cumference.	A	6-year	prospective	study	conducted	among	Chinese	
diabetes	 cases	 reported	 log(TG/HDL-c)	 ratio	 was	 correlated	 with	
beta-cell dysfunction.66
3.2.6 | Antibodies and inflammatory markers
Glutamic	 acid	 decarboxylase	 antibodies	 (GADA)	 are	 a	marker	 of	
autoimmune beta-cell damage and are one of the major predictors 
of	progression	to	insulin	therapy	in	type	2	diabetes.	Five	(one	pro-
spective and four retrospective) studies reported that the pres-
ence	of	GADA	 in	 type	2	diabetes	 increased	 the	 rate	of	diabetes	
progression denoted by insulin requirement44,57,58,67 and glycae-
mic deterioration.50	 These	 studies	were	 conducted	 in	European,	
Japanese	and	Korean	populations.	Similarly,	the	presence	of	islet-
cell	 antibodies	 (ICA)	 also	 shortened	 the	 time	 to	 insulin	 in	 type	
2 diabetes.44	 Autoantibodies	 to	 protein	 tyrosine	 phosphatase	
isoforms	 IA-2	 (IA-2A)	 were	 also	 associated	 with	 the	 time	 to	 in-
sulin	requirement	among	type	2	diabetes	 in	the	United	Kingdom	
Prospective	 Diabetes	 Study	 (UKPDS)33 and a Japanese study57; 
likelihood	 of	 insulin	 treatment	 almost	 doubled	when	GADA	 and	
IA-2	 antibodies	 were	 present	 in	 high	 titre.33	 Only	 one	 study	
has	 looked	 at	 inflammatory	 cytokines.	Here,	 a	 one-unit	 (1	 ng/L)	
increase	in	interleukin-6	(IL-6)	levels	was	associated	with	a	6%	in-
creased risk of insulin therapy over 4 years.52
3.2.7 | Beta-cell function
Three	prospective	 studies	 examined	 the	beta-cell	 function	by	ho-
moeostasis	 model	 assessment	 -beta	 (HOMA-B).	 Insulin	 initiation	
was	 the	outcome	 in	 two	 studies,	 and	diet	 therapy	 failure	was	 the	
outcome	of	 interest	 in	one	study.	All	 three	studies	concluded	that	
the	higher	the	baseline	beta-cell	function,	the	lower	the	rate	of	dia-
betes progression.44,52,71
3.2.8 | Other phenotypic factors
A	 cohort	 study	with	 2	 years	 follow-up	 showed	 the	 association	 of	
vaspin with diabetes progression. Vaspin is an adipocytokine which 
has	a	potential	insulin-sensitizing	effect.	Insulin	initiation	was	higher	
in the lower serum vaspin group indicating the effect of vaspin on 
progression.39	One	RCT,	two	retrospective	and	one	cross-sectional	
study evaluated the effect of tobacco smoking on diabetes progres-
sion,	 and	 all	 concluded	 that	 smoking	 was	 significantly	 associated	
with	the	diabetes	progression,	although	it	is	difficult	to	separate	this	
effect from other confounding variables such as social class.18,30,55,78 
Increased	fibroblast	growth	factor	21	 (FGF21),	a	peptide	hormone	
that	is	potentially	associated	with	weight	and	glycaemia,	was	associ-
ated with rapid diabetes progression.21 Hypertension and family his-
tory of diabetes were associated with time to insulin in trial data.55 
Finally,	basal	 insulin	 requirement	was	associated	with	alanine	ami-
notransferase	(ALT)	in	a	cross-sectional	study	which	assessed	insulin	
requirement.47
3.3 | Ethnicity
Most of the published studies reporting diabetes progression 
were	 conducted	 in	 White	 European	 diabetes	 populations,	 with	
seven	studies	examining	the	role	of	ethnicity	on	diabetes	progres-
sion	rates.	The	Look	AHEAD	trial	 reported	Black	 (aHR	0.66	95%	
CI	0.52-0.83)	and	Hispanic	(aHR	0.77	95%	CI	0.63-0.93)	diabetes	
groups have a slower rate of insulin initiation compared with their 
white counterparts.55	A	retrospective	study	conducted	in	US	vet-
erans	assessing	the	insulin	initiation	rate	in	White,	Hispanics	and	
Black	 also	 showed	 similar	 results.65 Two studies from Singapore 
reported	 Malayas	 and	 Indians	 had	 higher	 HbA1c	 levels	 relative	
to Chinese people with diabetes.48,68	 Another	 study	 reported	
that	Asians	 received	antidiabetic	prescriptions	earlier	 than	Black	
and	Latino	counterparts,	but	 this	difference	was	not	statistically	
significant.49 Ethnicity was not significantly associated with the 
initiation of antidiabetic drugs in a retrospective study includ-
ing	 Non-Hispanic	 white,	 Asian,	 African	 American	 and	 Latino	
ethnicities.34	 However,	 in	 a	 treatment	 intensification-based	
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study,	diabetes	progression	was	slower	in	participants	of	African	
American	ethnicity	compared	with	the	White	and	Hispanic	coun-
terparts.28 The limited data available do suggest ethnicity impacts 
on	diabetes	progression,	but	 there	 is	a	clear	research	gap	 in	this	
area.
3.4 | Genotypic determinants of diabetes 
progression
Five	 studies	were	 identified	 that	 assessed	genotypic	 factors	were	
associated with diabetes progression.74-78	Most	 of	 the	 studies	 ex-
amine the association with progression by developing a polygenic 
risk	score	(PRS).	A	PRS	is	constructed	to	aggregate	the	risk	contrib-
uted	by	different	genetic	variants	towards	a	disease	susceptibility.	In	
diabetes	progression	studies,	a	PRS	derived	from	diabetes	risk	vari-
ants,	a	PRS	derived	from	variants	related	to	Beta-cell	function	and	
a PRS derived from variants related to insulin resistance are mostly 
used	 (where	the	Beta-cell	 function	PRS	and	 insulin	resistance	PRS	
include diabetes risk variants that are a subset of the total PRS with 
evidence of association either with beta-cell function or with insulin 
resistance).80,81
A	case-control	study	among	those	with	Japanese	ethnicity	anal-
ysed association between PRS constructed from 11 SNPs associated 
with reduced beta-cell function (rs1111875 in HHEX, rs7756992 in 
CDKAL1, rs10811661 in CDKN2B, rs13266634 in SLC30A8, rs4402960 
in IGF2BP2, rs7903146 in TCF7L2, rs780094 in GCKR, rs7612463 in 
UBE2E2, rs7172432 in C2CD4A/B, rs2237892 in KCNQ1, and rs5219 
in KCNJ11)	and	whether	they	were	on	insulin	therapy.	In	this	crude	
study	of	diabetes	“progression,”	they	showed	a	nominally	significant	
association between this beta-PRS and insulin treatment (β	=	0.0131,	
SE	=	0.006,	P	=	.0431).74	Another	study	among	Japanese	population	
explored	the	association	between	a	single	nucleotide	polymorphism	
(SNP) in Syntaxin IA and insulin requirement in individuals with type 
2 diabetes. The CC genotype had a higher proportion of insulin ini-
tiation	events	compared	with	 the	other	genotypes,	 and	 this	 study	
revealed the SNP of Syntaxin IA was associated with insulin require-
ment in a Japanese population. Since the sample size of this study 
was	small	(n	=	182),	the	quality	of	evidence	was	low.77
The	 IMI-DIRECT	study	assessed	 the	association	between	 time	
to	insulin	requirement	and	PRS	(derived	from	61	type	2	diabetes	risk	
variants). Even though there was no significant association between 
time to insulin requirement and PRS in the Scottish diabetic popula-
tion,	the	PRS	was	associated	with	a	younger	age	of	diagnosis	and	a	
younger age of requirement of insulin.78	A	study	among	Caucasians	
assessed	 the	 peroxisome	 proliferator-activated	 receptor	 (PPAR)	
alpha gene polymorphism and progression to insulin therapy. The 
PPAR-alpha variant was significantly associated with time to insulin 
therapy	in	the	study	population,	but	no	replication	study	has	been	
reported.75	 In	 the	ADDITION-Denmark	 study,	 the	 association	 be-
tween a PRS (48 type 2 diabetes genetic risk variants) and time to 
first	prescription	(OHA	or	Insulin)	from	the	diagnosis	of	type	2	diabe-
tes	was	evaluated	in	patients	with	screen-detected	diabetes.	In	this	
study,	incident	cases	were	randomized	into	two	intervention	groups:	
a conventional group where the individual received usual care as per 
national	guidelines,	and	the	other	which	received	intensified	multi-
factorial intervention group with lifestyle counselling and additional 
management for blood pressure and cholesterol. While the overall 
PRS	did	not	 impact	on	diabetes	progression,	a	sub-PRS	that	 incor-
porated only diabetes risk variants linked with insulin resistance 
showed	association	with	time	to	insulin	prescription	(HR	1.39	(95%	
CI	1.09-1.77))	in	the	intensified	intervention	group.76
4  | DISCUSSION
Summary of findings:	 In	this	review,	we	 included	61	studies	explor-
ing the phenotypic or genotypic determinants of diabetes progres-
sion. Major phenotypic factors associated with increased rates of 
diabetes	progression	are	higher	HbA1c	at	diagnosis,	younger	age	of	
diabetes	onset,	higher	BMI,	lower	HDL-c	and	higher	triglyceride	lev-
els	at	baseline.	There	were	no	robust	genetic	associations,	although	
variants in PPAR-alpha,	Syntaxin IA and genetic risk scores associated 
with insulin resistance have been reported to be associated with dia-
betes progression.
Identification	of	both	phenotypic	and	genotypic	factors	associ-
ated with diabetes progression will help to recognize those whose 
glycaemia is likely to progress rapidly and provide intensified treat-
ment,	with	the	aim	of	reducing	the	probability	of	onset	of	diabetic	
complications and thereby reducing burden on healthcare systems. 
Early	intervention	may	also	help	to	tackle	the	“metabolic	memory”	
where early intensified treatment translates to better long-term con-
trol and lower complication rates.82 The majority of the phenotypic 
studies	were	conducted	in	European	and	American	populations	with	
diabetes	or	other	developed	countries,	but	the	burden	of	diabetes	is	
increasing in low- and middle-income countries. There is insufficient 
evidence to describe the ethnicity-based differences in diabetes 
progression; this is most likely to reflect the under-representation of 
all diabetes progression studies in non-white populations.
There was a wide variation in how diabetes progression was 
defined,	 with	 most	 of	 the	 studies	 defining	 it	 as	 the	 initiation	 of	
insulin42,43	with	 others	 defining	 it	 as	 the	 initiation	 of	 any	OHA	or	
treatment intensification. These prescription-based analyses can be 
affected	 by	 clinical	 inertia	 for	 prescribing	 “insulin.”	 Clinical	 inertia	
originates	 as	 a	 result	 of	 the	 complex	 interaction	between	patient,	
provider and health system factors and which delays the appropriate 
treatment regimes.83	The	Multinational	Diabetes	Attitudes	Wishes	
and	Needs	 (DAWN)	 study	 representing	13	 countries	 reported	 the	
reluctance among healthcare professionals to prescribe insulin.84 
Similarly	from	the	patient	level,	cultural	and	religious	beliefs	may	af-
fect the acceptance of insulin treatment.85 Some studies attempted 
to overcome this limitation by considering both glycaemic levels in-
dicative of insulin requirement and insulin prescriptions but the ma-
jority have not.78	 In	addition	 to	 this,	 there	 is	a	general	prescribing	
trend	of	 increasing	antidiabetic	 treatment	over	 time,	based	on	the	
introduction of newer drugs or changes in diabetes management 
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protocol across the countries.86 This could have affected the pro-
gression assessment based on the initiation of the antidiabetic drug.
Few	studies	have	attempted	to	analyse	the	effect	of	genotypic	
factors	on	diabetes	progression,	and	most	of	the	studies	were	from	
European and Japanese ethnicities. We need studies with more par-
ticipants to identify genetic variants or group of genetic variants in-
fluencing the diabetes progression.
Clinical interpretation: The consensus of the reported studies is 
that patients were more likely to progress whether they have high 
HbA1c,	 are	 GADA	 positive	 and	 have	 younger	 age,	 high	 BMI,	 low	
HDL-c	and	higher	triglycerides	at	baseline.	The	high	HbA1c	predict-
ing progression is no surprise and consistent with those having higher 
HbA1c	being	most	poorly	controlled	and	most	likely	to	fail	oral	treat-
ment	and	progress	 insulin.	The	presence	of	GAD	antibodies	should	
alert	 the	physician	to	the	 increased	risk	of	progression;	however,	 it	
should be noted that depending on the assay 2.5% to 5% of patients 
will	be	GAD	positive	by	chance	with	this	result	being	a	“false	posi-
tive.”	The	other	parameters	 reflect	a	more	rapid	progression	 in	pa-
tients	who	develop	diabetes	 younger,	who	are	usually	more	obese	
and	more	 insulin	 resistant	with	 adverse	 lipids.	 In	 the	 extreme,	 this	
is	described	in	the	TODAY	study	which	reported	on	type	2	diabetes	
diagnosed in youth.87	In	this	study,	nearly	half	progressed	to	the	point	
of	 treatment	 failure	 during	 the	 study,	 and	 half	 of	 these	within	 the	
first year. How should we treat those at high risk of progression? To 
date,	there	are	no	convincing	data	that	any	one	drug	of	the	many	now	
available	slows	progression	of	diabetes.	The	ADOPT	study	seemed	
to	 show	 a	 slower	 progression	 with	 TZDs	 compared	 to	 sulphony-
lureas	and	metformin,88 and this is particularly the case with obese 
women.89	Given	that,	once	diabetes	has	developed,	delaying	or	even	
stopping glycaemic deterioration in diabetes must be a key goal of 
diabetes	treatment,	it	is	surprising	that	more	studies	have	not	been	
undertaken	to	compare	progression	rates	between	drugs.	It	may	be	
that	 the	GRADE	 study	will	 be	 of	 value	when	 reported,90 although 
SGLT2	 inhibitors	were	not	 included	 in	this	study.	 In	the	absence	of	
any	particular	drug	to	delay	progression,	clinically	we	suggest	these	
high-risk patient subgroups should have regular intensive input from 
the	diabetes	multi-disciplinary	team,	with	a	focus	on	major	diet	and	
lifestyle intervention potentially with very low calorie diet91 or obe-
sity surgery.92
4.1 | Quality of evidence
Evidence from this review could be affected by the heterogeneity in 
the study population—a large percentage of studies are conducted 
among elderly patients with poor glycaemic control and this may 
introduce bias into the estimations. There were only a few stud-
ies which assessed diabetes progression across multi-ethnic dia-
betes	populations,	and	this	limits	our	insights	into	role	of	ethnicity	
in	diabetes	progression.	But	 in	all	 study	designs,	 from	prospective	
to	cross-sectional	 studies,	 the	 factors	 associated	with	progression	
were consistent and large sample size with a longer period of follow-
up in the observational studies provided good quality information. 
The evidence from this qualitative synthesis could be labelled as 
“moderate	quality”	based	on	the	above	observations.
In	conclusion,	the	phenotypic	and	genotypic	determinants	of	
diabetes progression identified in this review are glycaemic lev-
els,	age	of	onset	of	diabetes,	BMI	and	lipid	profile;	there	was	no	
robust genetic association. This review highlights the need for 
carefully performed multi-ethnic studies assessing glycaemic 
deterioration which will help to improve our understanding of 
diabetes progression. More genetics-based studies and pooled 
meta-analyses are required to validate the current findings on di-
abetes progression.
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